Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Terminated
Trial end date:
2016-02-23
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to determine the effect of simtuzumab (GS-6624) on
progression-free survival (PFS) as determined by either a categorical decline in forced vital
capacity (FVC) or all-cause mortality, in all participants enrolled or in a subset of
participants who are classified as lysyl oxidase-like-2 (LOXL2) high based on a prespecified
level in serum at baseline.